secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001683168-22-005186
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech rejects Iroquois Capital's consent solicitation to control board and cash reserves
--------------------------------------------------------------------------------

- Iroquois Capital, a 7% holder, seeks to expand board from 7 to 15 and elect 8 nominees to gain control of $80M+ cash.
- Company says Iroquois proposals are full of factual inaccuracies and would disenfranchise shareholders; urges ignoring consent cards.
- PharmaCyte states Iroquois slate has limited biopharma experience; claims seven similar Iroquois board additions led to avg 30%+ stock decline.
- Company reports ~90% of FDA clinical hold requests completed; two-phase pig study is last major item, progress could be jeopardized.
- PharmaCyte engaged in settlement talks with Iroquois but they rejected; Iroquois bought shares at low price and sold immediately, per company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005186/0001683168-22-005186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005186/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer